Terms: = Skin cancer AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1 AND Treatment
4 results:
1. Association of genetic polymorphisms of CYP3A4 and cyp2d6 with gefitinib-induced toxicities.
Kwok WC; Lam DCL; Ip MSM; Tam TCC; Ho JCM
Anticancer Drugs; 2022 Nov; 33(10):1139-1144. PubMed ID: 35946566
[TBL] [Abstract] [Full Text] [Related]
2. Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
Hirose T; Fujita K; Kusumoto S; Oki Y; Murata Y; Sugiyama T; Ishida H; Shirai T; Nakashima M; Yamaoka T; Okuda K; Ohmori T; Sasaki Y
Lung Cancer; 2016 Mar; 93():69-76. PubMed ID: 26898617
[TBL] [Abstract] [Full Text] [Related]
3. Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.
Sun B; Liu K; Han J; Zhao LY; Su X; Lin B; Zhao DM; Cheng MS
Bioorg Med Chem; 2015 Oct; 23(20):6763-73. PubMed ID: 26365710
[TBL] [Abstract] [Full Text] [Related]
4. Gefitinib.
Rahman AF; Korashy HM; Kassem MG
Profiles Drug Subst Excip Relat Methodol; 2014; 39():239-64. PubMed ID: 24794908
[TBL] [Abstract] [Full Text] [Related]